Lamotrigine - what else don’t we know about it? Unobvious uses of the drug based on clinical cases Case report
Main Article Content
Abstract
Lamotrigine is an antiepileptic and mood stabilizer widely used in neurology and psychiatry, both for its primary neurological indication – the treatment of epilepsy – and for its primary psychiatric indication – the treatment of bipolar disorder. Its mood stabilizing effects include preventing relapses of depression and mania and stabilizing rapid cycling. In acute depressive episodes, the drug may prove effective due to its additional antidepressant effect. Beyond these indications, however, there are a number of other situations in which lamotrigine may provide clinical benefits. Therefore, this article will address these applications of lamotrigine, discussing individual clinical cases and referencing the literature and research results confirming its efficacy in a given indication. We emphasize that clinical cases involve off-label use, which must be medically justified and reflected in the patient’s documentation. It must also be preceded by providing the patient with full information about the potential benefits and risks, as well as obtaining their consent. Although these indications are not registered indications for the drug, we decided to discuss them due to the large amount of scientific evidence confirming the benefits of such use, as well as our own observations from clinical practice.
Article Details
Copyright by Medical Education. All rights reserved.
References
2. Ade RM, Patil PS, Pathade A. The Therapeutic Role of Lamotrigine in Borderline Personality Disorder: A Comprehensive Review of Outcomes, Mechanisms, and Treatment Strategies. Cureus. 2024; 16(8): e6736.
3. Gerolymos C, Garosi A, Boyer L et al. Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis. Molecular Psychiatry. 2026; 31(6): 3216-28.
4. Pahwa M, Nuñez NA, Joseph B et al. Efficacy and Tolerability of Lamotrigine in Borderline Personality Disorder: A Systematic Review and Meta-Analysis. Psychopharmacol Bull. 2020; 50(4): 118-36. http://doi.org/10.64719/pb.4375.
5. Gałecki P, Bliźniewska-Kowalska K. Depresja oporna na leczenie – zalecenia Konsultanta Krajowego w dziedzinie psychiatrii. Psychiatria Polska. 2021; 55(1): 7-21. doi: 10.12740/PP/OnlineFirst/115208.
6. Bendtsen L, Zakrzewska JM, Abbott J et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019; 26(6): 831-49.
7. Kochanowski J, Cegielska J, Tomalka-Kochanowska J. Leki przeciwpadaczkowe w leczeniu bólu neuropatycznego. Aktualności Neurologiczne. 2009; 9(3): 209-13.
8. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol. 2001; 15: 297-301.
9. Tiihonen J, Hallikainen T, Ryynanen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003; 54: 1241-48.
10. D’ Andrea G, Granella F, Cadaldini M. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia. 1999; 19: 64-66.
11. Lampl C, Buzath A, Klinger D. Lamotrigine in the prophylactic treatment of migraine aura – an open pilot study. Cephalalgia. 1999; 19: 58-63.
12. Ranganathan LN, Ramamurthy G, Kanthimathinathan S. Preventive Oral Treatment of Episodic Migraine: An Overview. Neurol India. 2021; 69(Suppl): S51-S58.
13. Trunko ME, Schwartz TA, Marzola E et al. Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control. Int J Eat Disord. 2014; 47(3): 329-34.
14. Rybakowski J, Tuszewska M. Normotymiczne działanie lamotryginy. Farmakoterapia w Psychiatrii i Neurologii. 2004; 3: 325-34.
15. Samochowiec J, Rybakowski J, Galecki P et al. Rekomendacje Polskiego Towarzystwa Psychiatrycznego dotyczące leczenia zaburzeń afektywnych u kobiet w wieku rozrodczym. Część I: Leczenie depresji. Psychiatria Polska. 2019; 53(2): 245-62. http://doi.org/10.12740/PP/103385.
16. Battino D, Tomson T, Bonizzoni E et al.; EURAP Collaborators. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol. 2024; 81(5): 481-89. http://doi.org/10.1001/jamaneurol.2024.0258.
17. Cunnington MC, Weil JG, Messenheimer JA et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology. 2011; 76(21): 1817-23. http://doi.org/10.1212/WNL.0b013e31821ccd18.
18. U.S. Food and Drug Administration. Pregnancy and Lactation Labeling Final Rule [Internet]. Silver Spring (MD): FDA; 2014.